Table 3:
Adverse effects associated with celiac plexus neurolysis.
| AUTHOR | Procedure | Technique | n | Patients | % adverse effects | Transient hypotension | Local pain | Transient diarrhea | Lightheadedness or dizziness | Nausea or vomiting | Others adverse effects |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jain et al. 2005 |
PER-CPB | Posterior access, F-guide, 22G needle, lidocaine 1%, meglumine, OH 50% 20 ml | 48 | Age 48.6 vs 50.9 years. Male 50 vs 60%. PCa and gallbladder, pain with opioid use | 20.8 | 10 cases | No SC | ||||
| Zhang et al. 2007 |
PER-CPB | L1 posterior access, T-guide, 23G needle, 5 ml 1% lidocaine, 3 ml contrast, 20 ml 100% OH | 29 | Age 38-75 years. Male 62.5%. Chronic pain due to Pca | 34.5 | 10 cases (two persist until day 7 and one until day 14) | 2 cases (persist until day 7) | 5 cases (one persists until day 7) |
2 cases (only one day) |
No SC | |
| Amr et al. 2013 |
PER-CPB | Transaortic access, T12-L1, F-guide, 22G needle, 1% lidocaine, 70% OH. | 60 | Age 50 years +/- 11. Male 65%. Severe pain due to PCa with use of tramadol | 53.3 | 8 cases (13%) resolved with parenteral hydration | 32 cases (53.3%), resolved in 48 hours without treatment | No SC | |||
| Dolly et al. 2016 |
PER-CPB | Lateral access intervertebral disc (T12), F-guide, 25G needle, 2% lidocaine, 2 ml contrast, 70% OH (20, 30, and 40 ml) | 30 (10 per group) |
Age 25-70 years. Male 20%. Gallbladder Cancer Pain | 53.3 | 12 in the injection site and 8 mild back pain | 4 cases | No SC. No difference between groups | |||
| Abdelghaffar et al. 2019 | PER-CPB | Antecrural posterior access, T-guide, phenol 10% 25 ml in total. One and two needles | 30 (G1:17 G2:13) | Abdominal cancer pain | 40 | 8 cases | one case | One case of hemorrhage and 3 of local infection | |||
| Saeed et al. 2019 |
PER-CPB | Posterior access to body level L1, F-guide, lidocaine 2%, OH 15 ml (50 and 100%) | 100 (50 per group) | Age 57 years +/- 12. Male 54%. Inoperable PCa pain | 67 | 64 vs 70% according to study group | 64 vs 70% according to study group: mild back pain | 64 vs 10% according to study group | No SC. Greater adverse effects with OH 100% | ||
| Wyse et al. 2011 |
EUS-CPB | 19G needle, F-guide, bilateral injection of Bu 0.5% 10 ml and OH 100% 20 ml | 96 (48 per group) |
Age 66.5 years +/- 9. Male 49%. Pain due to Pca | 0 | Only reports complications that prolong hospitalization | No SC | ||||
| LeBlanc et al. 2011 |
EUS-CPB | US-Guide, injection at the level of the celiac trunk of 20 ml of Bu 0.75% + 10 ml of OH 98% (1 or 2 needles) | 50 (G1:29 G2:21) | Age 63 years. Male 48%. Pain due to Pca | 36 | One case (2%) that resolved with intravenous fluids | 18 cases (36%) post- procedure pain |
No SC | |||
| LeBlanc et al. 2013 |
EUS-CPB | US-guide, access to the posterior wall of the stomach, needle 22G, Bu 0.75% 20 ml and then OH 98% (10 or 20 ml) | 20 (10 per group) |
Age 66 years +/- 14. Male 55%. Inoperable PCa pain | 30 | 2 cases (temporary) | one case | 3 cases | No SC. No difference between groups | ||
| Kanno et al. 2020 |
EUS-CPB | Needle 22 or 25G, US-guide, Bu 0.25% 2-3 ml, solution 15-30 ml (iopaminol 5% + OH 99% 95%) | 24 | Age 69 years +/- 10. Male 50%. Severe cancer pain | 33.3 | 3 cases | 3 cases | 2 cases | No SC |
PER -CPB: Percutaneous Celiac plexus block, EUS -CPB: Endoscopic -ultrasound Celiac plexus block, PCa: Pancreas cancer, F: Fluoroscopic, T: Tomographic, US: Ultrasonographic, Bu: Bupivacaine; OH: Alcohol, SC: Severe complications